Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Redeye Fight Cancer 2026
18 slides from Expres2ion Biotech Holding Ab's conference presentation, Jan 21, 2026
Slide 1: The deadliest threat in women's health deserves a better defence
Redeye Fight Cancer, 21 January 2026 Keith Alexander, ExpreS2ion Biotech CFO The deadliest threat in women’s health deserves a better defence STO: EXPRS2 Hosted by ExpreS2ion Biotech Holding AB Org. Nr. 559033 - 3729
Slide 2: Breast Cancer: The #1 Killer in Women's Health
Breast Cancer: The #1 Killer in Women’s Health Current drugs save lives but leave too many behind HER2 Expression • 2.3 million women diagnosed each year 1 – the most common cancer HER2 globally receptor HER2 receptors • 685,000 annual deaths 1 – the leading cause of cancer mortality in send signals
Slide 3: Significant Market Opportunity
Significant Market Opportunity ES2B - C001 is a First - in- Class breast cancer immunotherapy, targeting the entire extracellular domain of HER2 Patient distribution by region and cancer type 1 Global market: HER2 - expressing breast cancer therapies exceeded €17B globally in 2024 2 1,000,000 Proven
Slide 4: ES2B-C001 – a First-in-Class BC Immunotherapy
ES2B - C001 – a First - in- Class BC Immunotherapy Based on technology already having clinical PoC and Phase III validation (COVID - 19, >4,000 subjects) HER2 protein • VLP concept exists in approved vaccines ; (all 4 extra - cellular domains, i.e. HPV vaccine against cervical cancer and polyclonal
Slide 5: Preclinical Proof-of-Concept: Robust Immune Response & Tumour Control
Preclinical Proof - of- Concept: Robust Immune Response & Tumour Control • Broad immune response Vaccine induced polyclonal Tumour - free survival 3 antibodies vs. HER2 Vaccine induced • Tumour growth inhibition A further advantage of ES2B - C001 over monoclonal antibodies was the induction of a bro
Slide 6: ES2B-C001 Phase I: Design, Progress, & Early Immunogenicity
ES2B - C001 Phase I: Design, Progress, & Early Immunogenicity Trial design Active patients in dose escalation Anti - HER2 λ light chain geometric • Population: ≤27 advanced HER2 - mean titer over time Patient Dosage* Doses Received Study Stage positive or HER2 - low breast cancer 12,500 patients (po
Slide 7: From First Signals to Pharma Deal
From First Signals to Pharma Deal Goal: Out - license when Phase II delivers proof — or earlier if signals are strong 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Phase I: First human data Phase II: Proof of concept in Breast Cancer Potential parallel Regist Phase II in Gastric Phase
Slide 8: Big Pharma Bets Billions on HER2 Therapies
Big Pharma Bets Billions on HER2 Therapies Multi- billion dollar M&A and licensing deals show strong demand for innovative HER2 treatments Key transactions Stage at Year Product - generic name Type Seller Acquirer Up - front ($M) Milestones ($M) Royalties Geography acquisition 2025 STX - 478 Small -
Slide 9: Pipeline Overview
Pipeline Overview Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform, and AdaptVac’s VLP in some cases Target Pre - clinical DISEASE Project/Target ID Identification Pharmacology cGMP / Tox Phase I Phase II Phase III Collaboration Partner Platform 1 100% Br
Slide 10: Extensive Clinical Development, Oncology & Licensing Experience
Extensive Clinical Development, Oncology & Licensing Experience Executive Management Fully capable of Bent U. Frandsen, CEO 30 years life science management, business development and finance executing to MSc, Copenhagen Business School experience phase II POC Dr. Max Søgaard, CSO 25 years research e
Slide 11: Upcoming Catalysts
Upcoming Catalysts Multiple value - driving readouts over the next 12 - 18 months ES2B - C001 | Breast cancer immunotherapy Additional near - term catalysts Malaria Now Next Later • BIO - 002 phase Ia data (Q1) Q1/Q2 ‘26 Q3/Q4 ‘26 2027+ • VAC089, BIO - 001 & VAC086 phase Ia/Ib data (Q3) Phase Ia Pha
Slide 12: Summary
Summary • Large unmet medical need • Significant market & revenue potential • Differentiated therapeutic approach • Strong preclinical proof - of- concept • Encouraging Phase I data • Multiple shots on goal • Experienced team with successful outlicensing track record • Catalysts ahead from clinical
Slide 13: Q&A
Q&A NASDAQ FN: EXPRS2 Innovative vaccines for a healthier world investor@ expres2ionbio.com https://investor. expres2ionbio.com
Slide 14: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to u nde rwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of
Slide 15: Summary – Pitch (to investors)
Summary – Pitch (to investors) • We are building long - term enterprise value, not optimizing for one - • Grants allow us to create real options efficiently. year P&L optics. Grant - backed projects run close to breakeven on a direct basis, Our model prioritizes investments that compound across prog
Slide 16: About ExpreS2ion
About ExpreS2ion From early contract research organisation (CRO) to primary focus on own pipeline assets Founding & Strategy Pipeline Projects Grants & CRO Business ES2B - C001 (HER2 Breast Cancer) Grant Initiatives - Grants fund platform development and IP, and can result in license Clinical trial
Slide 17: Pipeline overview
Pipeline overview Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform, often combined with AdaptVac’s VLP technology Target Pre - clinical DISEASE Project/Target ID Identification Pharmacology cGMP / Tox Phase I Phase II Phase III Collaboration Partner Platf
Slide 18: Upcoming Catalysts
Upcoming Catalysts Key target milestones in near future ES2B - C001 • Q1- Q4: Expanded safety and immunogenicity data + potential efficacy data • Q2/Q3: Completion of Phase Ia (dose escalation) Nipah • Q4: Completion of Phase Ib (expansion) • Q1: Initiation of CMC manufacturing • Beyond: Phase II tr
ExpreS2ion Biotech Holding — Redeye Fight Cancer 2026 on 6ix